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Materials/Methods: 1 participant ran on a treadmill that was 
accelerating between speeds of 0 and 18 Km/h in 2 minutes. 
CODA automated motion analysis system was used to collect 
3D kinematic data from 14 markers placed on the head, 
shoulders, elbows, wrists, hips, knees, ankles of the 
participant (sampling frequency 100 Hz, trial length 120 s). 
Marker position and acceleration data were analysed in the x, 
y and z directions. 
Individual and combined sensor measurements were 
resampled at 4000Hz to generate audible waveforms. 
Sonograms were then computed using moving Hanning 
windows for all the sound signals computed for each marker 
and combination of markers. 
Results: Sonification of individual and combined markers are 
shown in Figure 1. The transition between the walking and 
running gaits is clearly visible in all of the sonograms (Figure 
1). Sonification of individual markers (Figure 1, top left) 
shows the frequencies underpinning the marker movement. 
Combining the markers, sonification shows the cancellation 
and enhancement of frequencies involved in the gait as a 
result of coupling the marker waveforms (Figure 1, top right 
and bottom). 
 
 
Figure 1: Sonograms of vertical components of: Top left – 
left knee marker; Top right – Left leg = left knee, ankle and 
hip markers; Bottom left – Left leg combined with Right arm 
= right wrist, elbow and shoulder markers; Bottom right – 
Whole body = combined left leg, right leg, left arm, right 
arm and head markers 
 
Conclusion: Sonification provides a measure that clearly 
shows the phase transition between walking and running 
gaits. Furthermore, this measure is individual specific and 
situation specific. It is proposed that this method could be a 
used as a key tool for understanding and identifying and 
tracking changes in pathological or perturbed gaits; informing 
health practice.  
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Purpose: Cathepsin L (CTSL) has been shown to play a role in 
tumour development and progression through its proteolytic 
activities. An increased expression and secretion of CTSL 
from cancerous cells enhances the tumour cell migration, 
aids in tumour invasion and promotes angiogenesis. In the 
present study we have investigated the role of the small 
molecule cathepsin L inhibitor, KGP94, on tumour initiation 
and metastatic spread in murine tumour models.  
Methods: The C3H mammary carcinoma was implanted 
subcutaneously into the foot of male CDF1 mice. The SCCVII 
squamous cell carcinoma was either implanted into the foot 
or intravenously injected into the tail vein of C3H/HeNHsd 
mice. KGP94 was prepared by dissolving in a mixture of 10% 
Tween 80 and 90% HEPES-buffer. It was intraperitoneally 
(i.p.) injected at 0.01ml/g mouse bodyweight. Various doses 
(1-20mg/kg) were administered starting from the day of 
tumour implantation/injection. Tumour response was 
assessed by either determining the tumour growth time for 
foot tumours or the number of lung metastasis for the 
injections. Tumour growth time was assessed using a caliper 
and was the time in days to reach a volume of 500mm3 
(TGT500). Lung metastasis were assessed after 2-3 weeks, 
where mice were euthanized, lungs were excised, weighed, 
and stained in Bouin’s solution. Results are listed as Mean (± 
Standard Error). One-way ANOVA comparison of group means 
was performed, and a P<0.05 was considered significant. 
Results: The TGT500 for control animals was 18.3 days (± 0.4) 
for the C3H mammary carcinoma and 13.6 days (± 0.7) for 
the SCCVII carcinoma. Treating the C3H mammary carcinoma 
with KGP94 significantly increased the TGT500 when doses 
were at 5.0 mg/kg or higher. Similar results were found with 
the SCCVII-carcinoma, except that a dose of 5.0 mg/kg did 
not have a significant effect on TGT. At lower doses of KGP94 
neither of the tumour models showed significant growth 
delay. Studies on metastasis formation showed that 50% of 
animals in the control group developed metastasis within 2-3 
weeks. The mean number of metastasis in these mice was 16 
(±15). When mice were treated with KGP94 (10mg/kg) on a 
daily basis only 30% developed metastasis, and the mean 
number of metastasis in these mice was 5 (±4). 
Conclusion: We have shown that inhibiting cathepsin L during 
the tumour initiation stage significantly delays tumour 
growth in the C3H and SCCVII murine tumour models. 
Furthermore, our metastasis study showed decreased 
metastasis formation in KGP94 treated animals. This suggests 
that KGP94 treatment can affect both tumour initiation and 
metastasis formation. 
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Many human tumors contain substantial regions of low oxygen 
(hypoxia), which promotes metastasis and resistance to most 
forms of therapy. Unfortunately, the methods available to 
assess cellular hypoxia are unable to detect the fluctuating 
oxygen concentrations that are proposed to be an important 
source of these cellular phenotypes, and similarly cannot 
detect changes in hypoxia as a consequence of treatment. 
We have established a novel method that enables 
measurement of dynamic changes in hypoxia at the cellular 
level. We developed a series of small molecule probes with 
identical chemical structures but containing different 
isotopes of tellurium that can be independently quantified by 
mass cytometry (MC) and imaging mass cytometry (IMC). This 
